A correlation between impaired bone metabolism, chronic kidney disease, and\ncardiovascular diseases (CVD) has been suggested. This study aimed to compare the effects of\ndenosumab and alendronate, two anti-resorptive agents, on cardiovascular and renal outcomes in\nosteoporotic patients. Propensity score-matched cohort study comparing denosumab to alendronate\nusers between January 2005 and December 2017 was conducted from a large medical organization in\nTaiwan. Risks of CVD development and renal function decline were estimated using Cox proportional\nhazard regression. A total 2523 patients were recruited in each group. No significant difference in\ncardiovascular events was found between the two groups over a 5-year study period........................
Loading....